Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 212

1.

Vaccines as an Integral Component of Cancer Immunotherapy.

Schlom J, Gulley JL.

JAMA. 2018 Nov 8. doi: 10.1001/jama.2018.9511. [Epub ahead of print] No abstract available.

PMID:
30419097
2.

Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial.

Le Tourneau C, Hoimes C, Zarwan C, Wong DJ, Bauer S, Claus R, Wermke M, Hariharan S, von Heydebreck A, Kasturi V, Chand V, Gulley JL.

J Immunother Cancer. 2018 Oct 22;6(1):111. doi: 10.1186/s40425-018-0424-9.

3.

Finding an Immunologic Beachhead in the Prostate Cancer Microenvironment.

Madan RA, Gulley JL.

J Natl Cancer Inst. 2018 Oct 13. doi: 10.1093/jnci/djy145. [Epub ahead of print] No abstract available.

PMID:
30321404
4.
5.

A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study.

Parsons JK, Pinto PA, Pavlovich CP, Uchio E, Kim HL, Nguyen MN, Gulley JL, Jamieson C, Hsu P, Wojtowicz M, Parnes H, Schlom J, Dahut WL, Madan RA, Donahue RN, Chow HS.

Eur Urol Focus. 2018 Sep 6. pii: S2405-4569(18)30235-9. doi: 10.1016/j.euf.2018.08.016. [Epub ahead of print]

PMID:
30197041
6.

Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1.

Mammen AL, Rajan A, Pak K, Lehky T, Casciola-Rosen L, Donahue RN, Lepone LM, Zekeridou A, Pittock SJ, Hassan R, Schlom J, Gulley JL.

Ann Rheum Dis. 2018 Sep 5. pii: annrheumdis-2018-213777. doi: 10.1136/annrheumdis-2018-213777. [Epub ahead of print] No abstract available.

PMID:
30185415
7.

Pembrolizumab: patient selection or immune intensification?

Madan RA, Gulley JL.

Nat Rev Urol. 2018 Oct;15(10):593-594. doi: 10.1038/s41585-018-0076-z. No abstract available.

PMID:
30131600
8.

First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors.

Strauss J, Heery CR, Kim JW, Jochems C, Donahue RN, Montgomery AS, McMahon S, Lamping E, Marté JL, Madan RA, Bilusic M, Silver MR, Bertotti E, Schlom J, Gulley JL.

Clin Cancer Res. 2018 Aug 21. doi: 10.1158/1078-0432.CCR-18-1512. [Epub ahead of print]

PMID:
30131389
9.

White paper on microbial anti-cancer therapy and prevention.

Forbes NS, Coffin RS, Deng L, Evgin L, Fiering S, Giacalone M, Gravekamp C, Gulley JL, Gunn H, Hoffman RM, Kaur B, Liu K, Lyerly HK, Marciscano AE, Moradian E, Ruppel S, Saltzman DA, Tattersall PJ, Thorne S, Vile RG, Zhang HH, Zhou S, McFadden G.

J Immunother Cancer. 2018 Aug 6;6(1):78. doi: 10.1186/s40425-018-0381-3.

10.

Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy.

Collins JM, Redman JM, Gulley JL.

Expert Rev Vaccines. 2018 Aug;17(8):697-705. doi: 10.1080/14760584.2018.1506332. Epub 2018 Aug 22.

PMID:
30058393
11.

Editorial: Local Immunotherapy: A Way to Convert Tumors From "Cold" to "Hot".

Bilusic M, Gulley JL.

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx132. No abstract available.

PMID:
30053078
12.

Avelumab: is it time to get excited?

Marciscano AE, Gulley JL, Kaufman HL.

Expert Rev Anticancer Ther. 2018 Sep;18(9):815-821. doi: 10.1080/14737140.2018.1493380. Epub 2018 Jul 2. No abstract available.

PMID:
29939083
13.

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.

Boyiadzis MM, Kirkwood JM, Marshall JL, Pritchard CC, Azad NS, Gulley JL.

J Immunother Cancer. 2018 May 14;6(1):35. doi: 10.1186/s40425-018-0342-x.

14.

Morphological changes induced by intraprostatic PSA-based vaccine in prostate cancer biopsies (phase I clinical trial).

Merino MJ, Pinto PA, Moreno V, Gil S, Schlom J, Gulley JL.

Hum Pathol. 2018 Aug;78:72-78. doi: 10.1016/j.humpath.2018.04.013. Epub 2018 Apr 30.

PMID:
29709495
15.

A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-Targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer.

Harmon SA, Bergvall E, Mena E, Shih JH, Adler S, McKinney Y, Mehralivand S, Citrin DE, Couvillon A, Madan RA, Gulley JL, Mease RC, Jacobs PM, Pomper MG, Turkbey B, Choyke PL, Lindenberg ML.

J Nucl Med. 2018 Nov;59(11):1665-1671. doi: 10.2967/jnumed.117.207373. Epub 2018 Mar 30.

PMID:
29602821
16.

Perspectives on the clinical development of immunotherapy in prostate cancer.

Cordes LM, Gulley JL, Madan RA.

Asian J Androl. 2018 May-Jun;20(3):253-259. doi: 10.4103/aja.aja_9_18. Review.

17.

Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials.

Kelly K, Infante JR, Taylor MH, Patel MR, Wong DJ, Iannotti N, Mehnert JM, Loos AH, Koch H, Speit I, Gulley JL.

Cancer. 2018 May 1;124(9):2010-2017. doi: 10.1002/cncr.31293. Epub 2018 Feb 22.

18.

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors.

Strauss J, Heery CR, Schlom J, Madan RA, Cao L, Kang Z, Lamping E, Marté JL, Donahue RN, Grenga I, Cordes L, Christensen O, Mahnke L, Helwig C, Gulley JL.

Clin Cancer Res. 2018 Mar 15;24(6):1287-1295. doi: 10.1158/1078-0432.CCR-17-2653. Epub 2018 Jan 3.

PMID:
29298798
19.

Avelumab demonstrates promise in advanced NSCLC.

Marciscano AE, Gulley JL.

Oncotarget. 2017 Nov 13;8(61):102767-102768. doi: 10.18632/oncotarget.22418. eCollection 2017 Nov 28. No abstract available.

20.

Checkpoint and PARP inhibitors, for whom and when.

Lee JM, Gulley JL.

Oncotarget. 2017 Sep 12;8(56):95036-95037. doi: 10.18632/oncotarget.20852. eCollection 2017 Nov 10. No abstract available.

Supplemental Content

Loading ...
Support Center